Brief: NKGen Biotech Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq On Mar 11
15/03/2024 21:45
March 15 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH : ON MAR 11, RECEIVED NOTICE OF DELISTING OR
FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM
NASDAQ
Source text for Eikon: ID:n0001104659-24-035067
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program